HighVista Strategies
LBRX icon

HighVista Strategies’s LB Pharmaceuticals LBRX Stock Holding History

HighVista Strategies’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.86M Buy
211,511
+37,916
+22% +$1.11M 1.57% 17
2026
Q1 		$4.28M Buy
173,595
+33,488
+24% +$772K 1.18% 16
2025
Q4 		$3.12M Buy
+140,107
New +$2.45M 0.8% 38

Other funds holding LBRX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Trails Edge Capital Partners
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $510M AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

HighVista Strategies's LBRX Position: Q2 2026 in Review

HighVista Strategies increased its LB Pharmaceuticals (LBRX) stake by 22% in Q2 2026, buying an estimated $1.11M and bringing the position to 211,511 shares worth $6.86M. The position accounts for 1.57% of the portfolio, ranked #17.

HighVista Strategies first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • HighVista Strategies held 211,511 shares of LB Pharmaceuticals worth $6.86M as of Q2 2026.
  • HighVista Strategies bought 37,916 LB Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
  • LB Pharmaceuticals made up 1.57% of HighVista Strategies's portfolio in Q2 2026, its #17 holding.
  • HighVista Strategies first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.